Close

Chimeric Antigen Receptor (CAR) Design and Construction Services

Discover the power of CAR technology with tailored design and construction services to enhance precision, safety, and therapeutic impact. From innovative constructs to advanced generations, Creative Biolabs is committed to driving your research forward and accelerating your journey to clinical breakthroughs.

Get a Quote Now

Chimeric antigen receptor (CAR) T cell therapy represents a groundbreaking advancement in the fight against cancer and other diseases. However, each step, from selecting appropriate antigen-binding domains to optimizing CAR structural components, is crucial for developing CARs with high specificity and effectiveness. Understanding these complexities, we are committed to providing comprehensive CAR design and construction services tailored to meet the unique requirements of each project. Whether it's conventional or novel designs, our experienced team employs innovative thinking to ensure each CAR we help construction maximizes efficacy and safety.

Utilizing advanced bioinformatics tools and molecular biology techniques, we guide clients through the complex CAR development process from initial conceptualization to final validation. Our services are designed to accelerate research and development timelines, facilitating swift transitions from the lab to clinical applications. Whether your focus is on hematologic malignancies, solid tumors, or exploring CAR applications in autoimmune diseases, our goal is to support your work by providing cutting-edge solutions and expert guidance. Partner with us to access rich knowledge and resources dedicated to advancing the frontier of cellular immunotherapy.

Fig. 1 Chimeric antigen receptor design and construction services. (Creative Biolabs Authorized)

Chimeric Antigen Receptor Design

Fig. 2 Basic structure of a chimeric antigen receptor. (Creative Biolabs Original)
  • CAR components design
  • DIY your own design

CAR Construction & Validation

Fig. 3 Chimeric antigen receptor design. (Creative Biolabs Original)
  • Gene sequence design and optimization
  • Vector selection

Verification and Validation

Fig. 4 CAR vector construction. (Creative Biolabs Original)
  • Sequence verification
  • Expression validation
  • Stability and functional testing

Chimeric Antigen Receptor Design

At the forefront of CAR-T therapy development, our CAR Design services aim to create highly effective and targeted therapies for various cancers. By leveraging advanced design strategies, we ensure that each component of the CAR is optimized for peak performance. Our approach encompasses both established and innovative CAR formats tailored to meet specific therapeutic needs. Additionally, we prioritize humanization and low immunogenicity to enhance the safety and effectiveness of our CAR constructs.

CAR components design

Fig. 5 CAR cell verification and validation. (Creative Biolabs Original) Antigen-binding region (scFv)
We design scFvs with high affinity and specificity to the target antigen. Our team further optimizes scFv sequences through computational modeling, enhancing stability and reducing immunogenicity. Learn more about our ScFv Generation Services.
Fig. 6 Antigen-binding region (scFv) of a chimeric antigen receptor. (Creative Biolabs Original)Hinge and trans-membrane domain
We adjust the hinge region based on antigen spatial distribution, ensuring optimal flexibility and activity during antigen binding. We offer a range of transmembrane domain options with enhanced CAR surface expression and function.
Fig. 7 Hinge and trans-membrane domain of a chimeric antigen receptor. (Creative Biolabs Original)Co-stimulatory and signaling domain
By incorporating different generations of co-stimulatory domains, we can fine-tune the strength, duration, and safety of T cell activation. This flexibility allows us to customize CAR designs for a variety of therapeutic applications.
Different generations of CAR designs
Innovative CAR formats

These designs focus on modifying the basic structural components of CARs to optimize their binding and recognition capabilities.
Categories Designs Features
Specific Binding Domain Modifications VHH-based CAR Construction Uses single-domain antibodies derived from camelids, offering smaller size and better tissue penetration.
Adnectin-Based CAR Construction Employs engineered fibronectin type III domains as targeting molecules, providing high stability and specificity.
Peptide-centric CAR Construction Utilizes synthetic peptides as targeting domains, allowing for highly customizable antigen recognition.
TCR-fused Antigen Binding Receptor (TCR-ABR) CAR Construction Combines TCR and CAR technologies to enhance recognition of intracellular antigens.
CD3ε-Based CAR Design & Construction Incorporates CD3ε signaling components to improve T cell activation and signal transduction.
Immune Receptor Integration NKG2D-based Multi-target CAR Construction Service Utilizes natural killer cell receptors to target stress-induced ligands on tumor cells.
KIR CAR Construction Incorporates killer cell immunoglobulin-like receptors for enhanced tumor recognition.
γδ CAR-T Cell Development Combines γδ T cell properties with CAR technology for broader antigen recognition.
These designs incorporate various control mechanisms to regulate CAR-T cell activity and enhance safety profiles.
Categories Designs Features
Controllability Designs Smarter™ Self-destruct CAR Construction Includes a suicide switch mechanism for controlled elimination of CAR-T cells if needed.
Smarter™ Switch CAR-T Construction Features an on/off switch system for regulated CAR-T cell activity.
FR806-based Switchable CAR Construction Uses small molecule-dependent activation for controlled CAR-T cell function.
Smarter™ Orthogonal Dual-Switch CAR Construction Incorporates two independent control switches for enhanced safety and specificity.
Smarter™ Chemically Programmed Switch CAR Construction Enables chemical regulation of CAR-T cell activity through specific molecular triggers.
Avidity-controlled CAR (AvidCAR) Construction Allows fine-tuning of CAR-T cell binding strength to target cells.
Logic Gate Control Logic-gated CAR Construction Uses Boolean logic gates to create complex activation requirements.
Modular CAR (modCAR) Construction Features interchangeable components for customizable CAR function.
These designs aim to improve the overall performance and effectiveness of CAR-T cell therapy.
Categories Designs Features
Functional Enhancement Smarter™ Armored CAR Construction Includes additional protective features to enhance CAR-T cell survival in hostile tumor environments.
Smarter™ 7 × 19 CAR Construction Optimized design incorporating multiple improvements for enhanced efficacy.
c-Jun Overexpressed CAR Construction Features increased c-Jun expression to improve T cell function and persistence.
IL-8R-modified CAR Construction Incorporates IL-8 receptor modifications for better tumor trafficking.
Chimeric Costimulatory Antigen Receptor-T Construction Includes enhanced costimulatory domains for improved T cell activation.
Co-Stim CAR Design Features optimized costimulatory signaling for enhanced T cell function.
Multi-Target Strategies TriCAR Construction Targets three different antigens simultaneously for improved efficacy.
Compound CAR (cCAR) Construction Combines multiple CAR specificities in a single construct.
pan-ErbB-targeted Combination CAR-T Cell Targets multiple members of the ErbB family simultaneously.
These designs address specific challenges or applications in CAR-T cell therapy.
Categories Designs Features
Universal Platforms Smarter™ Universal ZipCAR Construction Provides a platform for rapid adaptation to different targets using zip-like connectors.
NKG2D-based Universal CAR Engineering Service Using TIM Molecule Combines NKG2D recognition with TIM molecules for broader applicability.
Synthetic T Cell Antigen Receptor (STAR) Construction Uses synthetic biology principles to create highly engineered receptor systems.
Special Applications PD-1-disrupted CAR Construction Includes PD-1 knockout for enhanced performance in immunosuppressive environments.
CRISPR/Cas9-based CAR Construction Uses CRISPR technology for precise genetic modifications in CAR-T cells.
CAR-Macrophage Adapts CAR technology for use in macrophages instead of T cells.
CAR-NK Vector Design and Construction Adapts CAR technology for use in Natural Killer cells.
Smarter™ Safety CAR Construction Incorporates multiple safety features for improved clinical safety.
CART Engineering Service Targeting TRBCs for T-cell Malignancies Immunotherapy Specifically designed for targeting T-cell malignancies.
CART Engineering Strategies for In Vivo Imaging Detection Includes imaging markers for tracking CAR-T cells in vivo.
Infographic Evolution of Chimeric Antigen Receptor Design This infographic presents the design of chimeric-antigen receptors (CARs), including:
  • CAR design and evolution
  • Comparison of different generations of CAR
  • Blueprint of CAR design
Fig. 19 DIY your own chimeric antigen receptor design. (Creative Biolabs Original)
We have developed a proprietary online system for customizing CAR and CAR cell products, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
DIY your own design

CAR Construction & Validation

1. Gene Sequence Design & Optimization

Starting with CAR gene sequence selection and codon optimization for efficient translation. Incorporates synthetic elements like promoters and signal peptides for optimal T cell expression.

2. Vector Selection

Evaluation of viral (lentiviral, adenoviral) and non-viral systems based on specific needs. Includes plasmid vectors and mRNA-based systems for reduced mutagenesis risk.

3. Cloning & Plasmid Construction

Multi-step cloning using restriction enzyme digestion and Gibson assembly for precise CAR gene integration. Focus on high-quality plasmid production.

4. Sequence Verification

Rigorous verification through Sanger and next-generation sequencing to confirm correct orientation and assembly of all components.

5. Expression Validation

Assessment of CAR expression via flow cytometry, Western blotting, and immunofluorescence to verify proper protein levels and localization.

6. Stability & Functional Testing

Extended culture period testing for CAR stability, cytotoxicity assays, and cytokine release evaluation to confirm therapeutic potential.

Case Study

Case Study: Creative Biolabs' Custom CAR Constructs in Enhancing T-cell Therapy for Solid Malignancies1

Creative Biolabs' Contribution

Creative Biolabs provided custom-designed CAR constructs essential for this study. The anti-ROR1-28z CAR and the anti-EGFRvIII-28z CAR constructs were tailored to target tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor variant III (EGFRvIII), respectively.

scFvs Engineering
Specifically engineered to recognize and bind to the targeted antigens, ROR1 and EGFRvIII.
Receptor Skeleton
Incorporating CD8 hinge, CD28 transmembrane and signaling domains, and CD3z signaling domain.
c-Myc Tag
Facilitating identification and tracking of transduced T cells during experiments.
Background
Solid tumors present significant challenges to immunotherapy due to their immunosuppressive microenvironment. Conventional CAR-T cell therapies have shown limited efficacy against solid malignancies, necessitating novel approaches to enhance their effectiveness. The study aimed to develop a method to remodel the tumor microenvironment, enabling CAR-T cells to effectively target and destroy breast cancer cells.
Methodology
The researchers utilized a murine 4T1 breast cancer cell line and a glioma mouse model to study the effects of combining targeted lipid nanoparticles with CAR-T cell therapy. The nanoparticles were designed to deliver a combination of a PI3K inhibitor (PI-3065) to inhibit immune-suppressive tumor cells and an NKT cell agonist (7DW8-5) to stimulate therapeutic T cells. The nanoparticles were administered in repeated infusions and were targeted to the tumor site using the iRGD peptide. Following nanoparticle preconditioning, tumor-specific CAR-T cells were infused during a therapeutic window created by the preconditioning. The effectiveness of the treatment was measured by assessing tumor regression, T-cell infiltration, and survival rates in treated animals.
Results
Improved Tumor Infiltration
The study found that CAR-T cells administered after nanoparticle preconditioning showed significantly higher infiltration into tumors compared to those without preconditioning. The bioluminescence imaging and flow cytometry confirmed that preconditioned tumors had a higher presence of CAR-T cells.
Enhanced Antitumor Activity
The combination therapy led to robust expansion of CAR-T cells at the tumor site, resulting in substantial tumor regression and prolonged survival in treated animals. In the 4T1 breast cancer model, mice treated with the combination therapy showed tumor stasis for up to 30 days, and in the glioma model, survival was more than doubled compared to conventional CAR-T cell therapy.
Reduction in Immunosuppressive Cells
The nanoparticle treatment effectively reduced the number of immune-suppressive cells within the tumor microenvironment. This included significant reductions in tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), creating a more favorable environment for CAR-T cell activity.
Reference
  1. Zhang, Fan, et al. "Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies." Cancer research 78.13 (2018): 3718-3730.


Why Choose Creative Biolabs

15+
Years Experience
2000+
Projects Delivered
100%
Client Satisfaction
Technical Expertise

Our team brings deep expertise in CAR-T therapy, developing both conventional and novel CAR formats. We leverage advanced techniques to ensure each CAR design maximizes therapeutic efficacy while minimizing potential risks.

Advanced Innovation

Creative Biolabs advances CAR development through innovative designs, including Tandem CARs, CRISPR/Cas9-based CARs, and Smarter™ self-destruct CARs, enabling more precise and safer therapies.

Rigorous Quality Control

Our verification and validation processes guarantee the accuracy, functionality, and stability of CAR constructs. This thorough approach ensures that you receive reliable, validated designs ready for downstream applications.

Streamlined Development Process

We accelerate research timelines through an integrated process combining CAR design, vector construction, and thorough testing. Our approach enables efficient progression from research to clinical applications.

Tailored Solutions

We provide customizable CAR design and vector construction options to meet your specific therapeutic goals. Our flexibility in design and optimization ensures solutions tailored to your research needs.

Tailored Solutions

Our experienced scientific team provides dedicated consultation throughout your project lifecycle. We offer strategic guidance and technical expertise backed by extensive practical experience in CAR-T development.



Trusted By Industry Leaders

OUR VALUED
PARTNERSHIPS

Frequently Asked Questions

What information or materials do I need to provide to start the CAR design process?
To initiate the CAR design and construction process, we typically require a few key pieces of information. First, we need details about the specific target antigen or antigens you want to address. If you have any data on the antigen's expression profile or binding characteristics, that would be extremely helpful. Additionally, sharing any preferences regarding the structure of the CAR (e.g., co-stimulatory domains, signaling domains, or transmembrane regions) allows us to customize the design more effectively. If you have existing sequences for the antigen-binding domain (such as an scFv) or previous constructs you've worked on, providing those sequences can help accelerate the process. If you're starting from scratch, don't worry—we can also assist with identifying the appropriate components for your CAR based on your therapeutic or research goals.
What deliverables can I expect from your CAR design and construction service?
Our CAR design and construction service provides a comprehensive set of deliverables to ensure you have everything you need to move forward with your project. You will receive a fully optimized CAR construct that includes the gene sequence of the entire CAR, designed according to your specifications. We also offer gene sequence optimization to improve expression and reduce potential immunogenicity. Depending on your needs, we can provide the CAR in different vector formats, such as plasmid, lentiviral, or adenoviral vectors, which are fully validated for functionality. Additionally, you will receive detailed reports on sequence verification (e.g., Sanger or next-generation sequencing), expression validation (using methods like flow cytometry or Western blot), and functional testing results, such as cytotoxicity assays. These deliverables give you a fully functional and validated CAR, ready for further in vitro or in vivo studies.
Can I select specific services or customize the package based on my needs?
Yes, our services are fully customizable to fit the unique requirements of your project. Whether you need only a specific aspect of the CAR-T development process—such as the design of the CAR structure, vector construction, or validation testing—we can provide standalone services. For example, if you have already designed your own CAR but need assistance with cloning and vector construction, we can handle that part of the process. Alternatively, if you need a complete solution from design to functional validation, we can offer an end-to-end service. You are not locked into a one-size-fits-all package. We encourage clients to discuss their specific goals and challenges with our team so we can create a custom service plan that suits their budget and timelines.
How will I be involved in the design and development process?
Our approach to CAR design and construction is highly collaborative, ensuring that you are actively involved at every critical step of the process. From the initial consultation, we work closely with you to understand your project's objectives, therapeutic targets, and any preferences you have for the CAR's structure. Throughout the design phase, we will provide regular updates and involve you in key decisions, such as selecting co-stimulatory domains, antigen-binding regions, and vector options. As the project progresses, you will receive milestone reports, and we will schedule review meetings to discuss any necessary adjustments. This level of engagement ensures that the final CAR construct fully aligns with your expectations and research goals. Your feedback is valuable at every stage, and our team is always available to answer questions and make modifications as needed.
Are there options to scale up the production of CAR constructs after initial design and validation?
Yes, we offer scalable solutions that can support your project as it moves from research and development into preclinical or clinical phases. Once your CAR design has been finalized and validated, we can assist with scaling up production based on your specific needs. For example, if you require large-scale plasmid production for further in vitro testing or therapeutic applications, we offer high-quality plasmid preparation in various purity grades. Additionally, we provide viral packaging services, such as lentiviral and adenoviral production, which are suitable for both small-scale studies and larger-scale applications. Our team can help you transition smoothly to higher quantities of CAR constructs for preclinical studies or clinical-grade production. Furthermore, we ensure that all large-scale products undergo the same rigorous quality control and validation processes to maintain consistency and reliability as your project scales.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.